SM
RCKT icon

Sabby Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Sabby Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27
Closed -$65K – 300
2016
Q4 		$65K Hold
27
– – ﹤0.01% 279
2016
Q3 		$100K Buy
+27
New +$849 ﹤0.01% 290

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management's RCKT Position: Q3 2017 in Review

Sabby Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 53,163 shares — an estimated $404K sold.

Sabby Management first reported a position in RCKT in Q3 2015 and held it in 8 quarters. The position peaked at $1.36M in Q3 2016. 34 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • Sabby Management reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 53,163 Rocket Pharmaceuticals shares in Q3 2017, an estimated $404K.
  • Sabby Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 8 quarters.
  • Sabby Management's Rocket Pharmaceuticals position peaked at $1.36M in Q3 2016.
  • 34 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.